Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
<p>Abstract</p> <p>Background</p> <p>Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of non-adherence and impact of non-...
Main Authors: | Kooij J J Sandra, Rösler Michael, Philipsen Alexandra, Wächter Sandra, Dejonckheere Joachim, van der Kolk Annemarie, van Agthoven Michel, Schäuble Barbara |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-01-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-244X/13/36 |
Similar Items
-
Editorial: Attention and Methylphenidate
by: Avi Avital, et al.
Published: (2020-04-01) -
Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II)
by: Philip Asherson, et al.
Published: (2019-12-01) -
Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder
by: Chou WJ, et al.
Published: (2018-10-01) -
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
by: Joseph A, et al.
Published: (2016-03-01) -
A Quasi-Experimental Trial in Comparison of Duloxetine and Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder
by: Nasrin Dodangi, et al.
Published: (2016-06-01)